Mogamulizumab (Poteligeo)

Mechanism of action

From the NCI Drug Dictionary: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons.

Diseases for which it is used

• Adult T-cell leukemia-lymphoma
• Cutaneous T-cell lymphoma
• Peripheral T-cell lymphoma

History of changes in FDA indication

• 8/8/2018: Initial FDA approval "for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy."

Also known as

• Code name: KW-0761
• Generic name: mogamulizumab-kpkc
• Brand name: Poteligeo